About
Specialty Pharmaceuticals
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Clinical Trials (23)
View allTotal Trials
23
As Lead Sponsor
23
As Collaborator
0
Total Enrollment
1,735
By Phase
PHASE3: 8PHASE2: 14
By Status
COMPLETED: 16TERMINATED: 3WITHDRAWN: 2NOT_YET_RECRUITING: 1NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline22 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT05249556Lead Sponsor
Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old
PHASE3Not yet recruiting
20 participants
Started: Dec 31, 2024 · Completed: Mar 31, 2027
NCT05814523Lead Sponsor
To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)
PHASE3Withdrawn
Started: Mar 31, 2024 · Completed: Aug 31, 2024
NCT05757544Lead Sponsor
Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)
PHASE2Withdrawn
Started: Apr 1, 2023 · Completed: Feb 28, 2026
NCT05604170Lead Sponsor
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
PHASE3Terminated
117 participants
Started: May 16, 2022 · Completed: Apr 2, 2025
NCT05323734Lead Sponsor
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
PHASE3Completed
129 participants
Started: Apr 1, 2022 · Completed: Oct 14, 2024
Locations (1)
Headquarters
Radnor, PA, United States
Map
Loading map...